The global market for genital herpes treatment market is anticipated to exhibit remarkable growth, with projections indicating that it surpasses the value of US$ 2.14 billion by the year 2023.
The upward trajectory is expected to continue, as the market is forecasted to achieve a significant compound annual growth rate (CAGR) of 5.2% through the year 2033, ultimately reaching an estimated value of US$ 3.55 billion. The figures highlight the growing demand and potential opportunities within the genital herpes treatment market on a global scale.
Research and development efforts have intensified within this dynamic market, aiming to enhance treatment options, efficacy, and patient outcomes. Further, the exploration of novel therapeutic approaches, such as antiviral drugs, immunotherapies, and gene therapies, has gained momentum, bringing new hope to individuals suffering from genital herpes.
| Attributes | Details |
|---|---|
| Genital Herpes Treatment Market Estimated Value (2023) | US$ 2.14 billion |
| Genital Herpes Treatment Market Estimated Value (2033) | US$ 3.55 billion |
| Genital Herpes Treatment Market Value CAGR (2023 to 2033) | 5.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Genital herpes cases are on the rise in the Western hemisphere especially in the United States of America, the United Kingdom, and Germany. The Centers for Disease Control and Prevention states that one out of every six people in the United States of America between the ages of 14 to 49 years is affected with genital herpes.
An increase in demand for genital herpes treatment is likely to create prospects for expansion of the market. FMI reports that the genital herpes treatment industry showcased a modest growth of 5.0% CAGR in the past five years.
Rising cases of genital herpes in countries in Asia such as China and India are projected to rev up growth opportunities for the market. The growth trend continues in response to increasing healthcare spending registered in emerging economies.
The market for genital herpes treatment is anticipated to experience continued growth and innovation. Projections indicate a substantial increase in market value, surpassing US$ 2.14 billion by 2023, with a CAGR of 5.2% from 2023 to 2033.
The genital herpes treatment market is expected to witness many significant advancements in therapeutic options. The emergence of gene therapies, nanomedicine approaches, and novel antiviral agents holds tremendous potential in revolutionizing the treatment landscape.
Detailed analysis of the genital herpes treatment market has provided researchers with crucial insights.
Principal Consultant
GEN-003 is potentially the first therapeutic vaccine for a chronic infection and represents a significant advancement in the treatment of genital herpes in over 20 years. It is an investigational immunotherapy for the treatment of genital herpes infections, and it is in the Phase 3-ready stage.
Genital Herpes Treatment Market:
| Attributes | Genital Herpes Treatment Market |
|---|---|
| CAGR (2023 to 2033) | 5.2% |
| Market Value (2033) | US$ 3.55 billion |
| Opportunity | Personalized medicine approaches in genital herpes treatment optimize outcomes by tailoring strategies based on individual profiles, improving patient satisfaction. |
| Key Trends | Advancing antiviral therapies in genital herpes treatment focus on developing effective, targeted drugs with novel mechanisms to improve outcomes and reduce viral replication, addressing the need for better therapeutic options. |
Herpes Labialis Treatment Market:
| Attributes | Herpes Labialis Treatment Market |
|---|---|
| CAGR (2023 to 2033) | 4.7% |
| Market Value (2033) | US$ 1.79 billion |
| Opportunity | Herpes labialis drug manufacturers might be presented with many opportunities due to the growing advances in the prevention of the virus. |
| Key Trends | The use of topical antiviral creams as the first line of treatment for herpes labialis is growing. It is predicted that this trend continues to increase the demand for these medicines. |
Herpes Simplex Virus Treatment Market:
| Attributes | Herpes Simplex Virus Treatment Market |
|---|---|
| CAGR (2023 to 2033) | 9.2% |
| Market Value (2033) | US$ 4.05 billion |
| Opportunity | The development of accurate and rapid diagnostic tests, including point-of-care testing and novel molecular techniques, can enable early detection and timely initiation of treatment, leading to improved patient outcomes and better disease management. |
| Key Trends | Researchers are exploring the potential of gene editing technologies and viral vectors to deliver therapeutic genes, offering a promising approach for long-term suppression or eradication of HSV infections. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Based on the FMI study, it is quite likely that the market for genital herpes treatment in North America remains supreme.
In 2022, the United States of America alone held a market share of 32.3%, and when considering the entire North America region, the market share was even high at 34.3%. These figures indicate a strong market presence and suggest that North America is a significant contributor to the market, and is likely to maintain its dominant position in the foreseeable future.
North America, particularly the United States, has robust regulatory bodies such as the Food and Drug Administration (FDA), which ensures the safety and efficacy of genital herpes treatment drugs.
The stringent regulatory framework instills confidence in market players and fosters a favorable environment for the development and commercialization of new treatments.
Both the United Kingdom and Germany allocate substantial healthcare budgets, which allows for investment in research, development, and access to advanced genital herpes treatments. This increased spending supports market growth and the development of innovative therapies.
There is growing awareness and education about sexually transmitted infections, including genital herpes, in both the United Kingdom and Germany. This heightened awareness encourages individuals to seek timely medical attention, driving the demand for genital herpes treatments and contributing to market expansion.
According to FMI, the market in Europe accounted for about 23.3% in 2022 while the market for genital herpes treatment in Germany contributed a 4.8% value share. The genital herpes treatment industry in the United Kingdom is anticipated to secure a CAGR of 6.9% from 2023 to 2033.
As per FMI projections, the market in India is predicted to advance at 8.0% CAGR during the forecast period.
India has a vast population, which directly translates into a significant patient pool for genital herpes treatment. The high prevalence of the infection drives the demand for effective treatment options, fostering market growth.
Pharmaceutical companies in India are actively engaged in research and development activities, including the development of new treatment options for genital herpes. These efforts contribute to the availability of innovative therapies in the market, supporting its growth.
Acyclovir is poised to lead the market based on drug type due to its strong attributes, with a value share of 51.11% in 2022.
Acyclovir provides healthcare providers and patients with reliable and versatile treatment options, with a proven track record of efficacy and safety, extensive clinical experience, and multiple available formulations. Additionally, the cost-effectiveness and ability to prevent drug resistance further contribute to its market dominance. These factors make Acyclovir a preferred choice and position it as a leader in the genital herpes treatment market.
Retail pharmacies are expected to be the prominent distribution channel for genital herpes treatment with a 46.1% value share in 2022 due to several reasons.
Retail pharmacies offer convenient access to medications, allowing patients to obtain prescribed treatments easily. Moreover, retail pharmacies provide a wide range of over-the-counter products, making them a one-stop destination for various healthcare needs.
The presence of knowledgeable pharmacists enables patient counseling, medication adherence support, and personalized recommendations, enhancing the overall patient experience. These factors contribute to the expectation that retail pharmacies play a significant role in the distribution of genital herpes treatment.
Top companies are playing a crucial role in shaping the global genital herpes treatment industry through their innovative products, extensive research and development efforts, strategic collaborations, and market expansion initiatives.
The companies invest in advanced technologies and clinical trials to develop new and effective treatment options for genital herpes. They also engage in strategic partnerships with healthcare organizations, research institutions, and other industry players to leverage collective expertise and resources.
Vaccine development for genital herpes is on the cards as pharmaceutical market leaders are focusing on new drug development. They are also collaborating with research institutes for clinical trials and faster product development.
Developments in the Market:
The industry is valued at US$ 2.4 million in 2023.
Key industry players in the Genital Herpes Treatment Market are Dr. Reddy’s Laboratories, Pfizer, and GlaxoSmithKline.
The pharmaceutical industry is the key consumer of the Genital Herpes Treatment Market.
The industry is estimated to reach US$ 3.5 million by 2033.
The Genital Herpes Treatment Market CAGR for 2033 is 5.2%.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Acyclovir 5.3.2. Valacyclovir 5.3.3. Famciclovir 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Hospital Pharmacies 6.3.1.1. Retail Pharmacies 6.3.1.2. Online Pharmacies 6.3.1.3. Drug Stores 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.3.4. Drug Stores 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Route of Administration, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Route of Administration, 2023 to 2033 7.3.1. Oral 7.3.2. Topical 7.3.3. Injectable 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2023 to 2033 8.3.1. HSV-1 8.3.2. HSV-2 8.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Type 10.2.3. By Distribution Channel 10.2.4. By Route of Administration 10.2.5. By Indication 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Distribution Channel 10.3.4. By Route of Administration 10.3.5. By Indication 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Argentina 11.2.1.4. Rest of Latin America 11.2.2. By Drug Type 11.2.3. By Distribution Channel 11.2.4. By Route of Administration 11.2.5. By Indication 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Distribution Channel 11.3.4. By Route of Administration 11.3.5. By Indication 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. UK 12.2.1.2. Germany 12.2.1.3. France 12.2.1.4. Italy 12.2.1.5. Spain 12.2.1.6. Rest of Western Europe 12.2.2. By Drug Type 12.2.3. By Distribution Channel 12.2.4. By Route of Administration 12.2.5. By Indication 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Distribution Channel 12.3.4. By Route of Administration 12.3.5. By Indication 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Russia 13.2.1.2. Poland 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Drug Type 13.2.3. By Distribution Channel 13.2.4. By Route of Administration 13.2.5. By Indication 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Distribution Channel 13.3.4. By Route of Administration 13.3.5. By Indication 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Drug Type 14.2.3. By Distribution Channel 14.2.4. By Route of Administration 14.2.5. By Indication 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Distribution Channel 14.3.4. By Route of Administration 14.3.5. By Indication 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Drug Type 15.2.3. By Distribution Channel 15.2.4. By Route of Administration 15.2.5. By Indication 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Distribution Channel 15.3.4. By Route of Administration 15.3.5. By Indication 15.4. Key Takeaways 16. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Iran 16.2.1.2. Turkey 16.2.1.3. Rest of MEA 16.2.2. By Drug Type 16.2.3. By Distribution Channel 16.2.4. By Route of Administration 16.2.5. By Indication 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Type 16.3.3. By Distribution Channel 16.3.4. By Route of Administration 16.3.5. By Indication 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Type 17.1.2.2. By Distribution Channel 17.1.2.3. By Route of Administration 17.1.2.4. By Indication 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Type 17.2.2.2. By Distribution Channel 17.2.2.3. By Route of Administration 17.2.2.4. By Indication 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Type 17.3.2.2. By Distribution Channel 17.3.2.3. By Route of Administration 17.3.2.4. By Indication 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Type 17.4.2.2. By Distribution Channel 17.4.2.3. By Route of Administration 17.4.2.4. By Indication 17.5. Argentina 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Type 17.5.2.2. By Distribution Channel 17.5.2.3. By Route of Administration 17.5.2.4. By Indication 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Type 17.6.2.2. By Distribution Channel 17.6.2.3. By Route of Administration 17.6.2.4. By Indication 17.7. Germany 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Type 17.7.2.2. By Distribution Channel 17.7.2.3. By Route of Administration 17.7.2.4. By Indication 17.8. France 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Type 17.8.2.2. By Distribution Channel 17.8.2.3. By Route of Administration 17.8.2.4. By Indication 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Type 17.9.2.2. By Distribution Channel 17.9.2.3. By Route of Administration 17.9.2.4. By Indication 17.10. Spain 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Type 17.10.2.2. By Distribution Channel 17.10.2.3. By Route of Administration 17.10.2.4. By Indication 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Type 17.11.2.2. By Distribution Channel 17.11.2.3. By Route of Administration 17.11.2.4. By Indication 17.12. Poland 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Type 17.12.2.2. By Distribution Channel 17.12.2.3. By Route of Administration 17.12.2.4. By Indication 17.13. Czech Republic 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Type 17.13.2.2. By Distribution Channel 17.13.2.3. By Route of Administration 17.13.2.4. By Indication 17.14. Romania 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Type 17.14.2.2. By Distribution Channel 17.14.2.3. By Route of Administration 17.14.2.4. By Indication 17.15. India 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Type 17.15.2.2. By Distribution Channel 17.15.2.3. By Route of Administration 17.15.2.4. By Indication 17.16. Bangladesh 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Type 17.16.2.2. By Distribution Channel 17.16.2.3. By Route of Administration 17.16.2.4. By Indication 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Type 17.17.2.2. By Distribution Channel 17.17.2.3. By Route of Administration 17.17.2.4. By Indication 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Type 17.18.2.2. By Distribution Channel 17.18.2.3. By Route of Administration 17.18.2.4. By Indication 17.19. China 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Type 17.19.2.2. By Distribution Channel 17.19.2.3. By Route of Administration 17.19.2.4. By Indication 17.20. Japan 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Type 17.20.2.2. By Distribution Channel 17.20.2.3. By Route of Administration 17.20.2.4. By Indication 17.21. South Korea 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Type 17.21.2.2. By Distribution Channel 17.21.2.3. By Route of Administration 17.21.2.4. By Indication 17.22. Iran 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Drug Type 17.22.2.2. By Distribution Channel 17.22.2.3. By Route of Administration 17.22.2.4. By Indication 17.23. Turkey 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Drug Type 17.23.2.2. By Distribution Channel 17.23.2.3. By Route of Administration 17.23.2.4. By Indication 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Type 18.3.3. By Distribution Channel 18.3.4. By Route of Administration 18.3.5. By Indication 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Teva Pharmaceutical Industries Ltd. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.1.5.2. Product Strategy 19.1.1.5.3. Channel Strategy 19.1.2. Abbott Laboratories 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.2.5.2. Product Strategy 19.1.2.5.3. Channel Strategy 19.1.3. Sun Pharmaceuticals Industries Ltd. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.3.5.2. Product Strategy 19.1.3.5.3. Channel Strategy 19.1.4. Mylan N.V. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.4.5.2. Product Strategy 19.1.4.5.3. Channel Strategy 19.1.5. Pfizer Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.5.5.2. Product Strategy 19.1.5.5.3. Channel Strategy 19.1.6. GlaxoSmithKline plc 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.6.5.2. Product Strategy 19.1.6.5.3. Channel Strategy 19.1.7. Dr. Reddy’s Laboratories, ltd. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.7.5.2. Product Strategy 19.1.7.5.3. Channel Strategy 19.1.8. Novartis AG 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.8.5.2. Product Strategy 19.1.8.5.3. Channel Strategy 19.1.9. Valeant Pharmaceuticals International Inc. etc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.9.5.2. Product Strategy 19.1.9.5.3. Channel Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Genital Herpes Treatment Market
